SW-682 for Advanced Solid Tumors with Hippo Pathway Mutations

This study is focused on testing a new drug called SW-682 in adults who have advanced solid tumors, which are types of cancer that have spread or cannot be removed by surgery. It is especially interested in patients whose cancer has certain changes in the Hippo pathway, a specific cell signaling pathway. These participants have already tried other treatments like chemotherapy or immunotherapy but have not had success, or they couldn't tolerate those treatments. The goal is to find a safe and effective dose of SW-682 for further research. This study is crucial as it can potentially offer a new treatment option for patients who have limited choices left due to the progression or resistance to existing therapies. Participants in this study will take the medication SW-682 orally, meaning they will swallow it, for a period of 28 days per cycle. The study is divided into two parts: the first part is to gradually increase the dose to see how much can be safely given, and the second part will expand the number of participants to further assess the effects at the chosen dose. Researchers will closely monitor how the body responds to the drug, focusing on safety and the drug's impact on the tumors. While potential benefits include discovering a new effective treatment, there are also risks, such as unknown side effects, since this is the first time SW-682 is being tested in humans.